XLO Q2 2022 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$29M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$25M

EPS (Diluted)

$-0.90

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$178M

Total Liabilities

$34M

Stockholders' Equity

$144M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$25M	-$23M	-6.7%
Net Income	-$25M	-$23M	-6.2%